4.5 Article

Targeted elimination of mutated mitochondrial DNA by a multi-functional conjugate capable of sequence-specific adenine alkylation

Journal

CELL CHEMICAL BIOLOGY
Volume 29, Issue 4, Pages 690-+

Publisher

CELL PRESS
DOI: 10.1016/j.chembiol.2021.08.003

Keywords

Sequence-selective mitochondrial DNA (mtDNA) alkylators; mitochondrial DNA (mtDNA) alkylators

Funding

  1. AMED [JP20am0101101]
  2. JSPS [18J21755, 19H03349, 16H06356, 20H05936]
  3. Takeda Science Foundation
  4. Naito Foundation
  5. NIH [R01CA236350]
  6. Hirose International Foundatio
  7. Grants-in-Aid for Scientific Research [20H05936, 19H03349, 18J21755] Funding Source: KAKEN

Ask authors/readers for more resources

This study constructed a class of compounds that can selectively alkylate mutant mitochondrial DNA, with the potential to treat mitochondrial diseases. These compounds have programmability and can be used to target pathogenic mutations associated with mitochondrial diseases in future studies.
Mutations in mitochondrial DNA (mtDNA) cause mitochondrial diseases, characterized by abnormal mitochondrial function. Although eliminating mutated mtDNA has potential to cure mitochondrial diseases, no chemical-based drugs in clinical trials are capable of selective modulation of mtDNA mutations. Here, we construct a class of compounds encompassing pyrrole-imidazole polyamides (PIPs), mitochondria penetrating peptide, and chlorambucil, an adenine-specific DNA-alkylating reagent. The sequence-selective DNA binding of PIPs allows chlorambucil to alkylate mutant adenine more efficiently than other sites in mtDNA. In vitro DNA alkylation assay shows that our compound 8950A-Chb(Cl/OH) targeting a nonpathogenic point mutation in HeLa S3 cells (m.8950G>A) can specifically alkylate the mutant adenine. Furthermore, the compound reduces the mtDNA possessing the target mutation in cultured HeLa S3 cells. The programmability of PIPs to target different sequences could allow this class of compounds to be developed as designer drugs targeting pathogenic mutations associated with mitochondrial diseases in future studies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available